Paediatric mycosis fungoides (MF) is characterized by early-stage disease, a strikingly indolent course and high rates of unusual variants. Despite these clinical pecularities and the special treatment-related safety considerations in children and adolescents, detailed published data on treatments of paediatric MF are scarce, and management is currently based primarily on standard practice in adults.
To develop therapeutic recommendations on behalf of the 3 largest societies for cutaneous lymphoma societies, ISCL, EORTC, and USCLC, specifically designed for MF in children and adolescents.
The guideline was developed through an international expert consensus process and in accordance with the EQUATOR Network's recommendations for guideline development. A modified Delphi process was conducted, using questionnaires covering treatment modalities that are recommended by international guidelines for adult MF. Two rounds of expert feedback were conducted, with an additional one hybrid consensus meeting.
Therapeutic recommendations were formulated focusing mainly on early-stage disease. These recommendations take into account disease-specific parameters with therapeutic implications, including the specific stage of the disease, the type of the lesion, and the presence of the folliculotropic variant, which is commonly observed in the paediatric age group. Patient-related factors, including safety concerns specific to this young age group, were also addressed.
This ISCL/EORTC/USCLC guideline provides up-to-date age-specific practical recommendations for the treatment of MF in children and adolescents.